Other World Computing and Hedge Deepen Partnership with OWC Innergize Integration into Hedge OffShoot
12.9.2025 08:30:00 CEST | Business Wire | Press Release
Other World Computing (OWC®), a trusted leader in high-performance storage, memory, connectivity, software, and accessories that empower creative and business professionals to maximize performance, enhance reliability, and streamline workflows, today announced an expanded partnership with Hedge. OWC’s Innergize™ software is now integrated into Hedge’s flagship media management and backup application, OffShoot, delivering creative professionals faster, safer, and more reliable workflows.
OffShoot is widely recognized as the industry standard for media offloading and backup. Built for macOS, it enables users to create multiple verified copies and archives from cards, drives, and other media simultaneously, with checksum verification to ensure absolute data integrity. With this integration, OffShoot users can now also take advantage of OWC Innergize’s unique ability to monitor card health, perform field firmware upgrades, and sanitize OWC Atlas memory cards for peak performance.
“Creative pros do their best work when their technology performs flawlessly,” said Larry O’Connor, Founder and CEO of Other World Computing (OWC). “OWC Atlas Memory Cards and Readers already deliver unmatched reliability and performance. By combining that with the industry-leading speed of Hedge OffShoot and the proactive health and performance tools of OWC Innergize, we give filmmakers, photographers, and content creators complete confidence that their footage is safe and their media is always ready for the next project.”
"Just like with any gear, people take great care of their camera cards,” said Paul Matthijs, CEO and Co-Founder, Hedge. “Now that OWC's Innergize technology is fully integrated with OffShoot, creators can do their health checks and maintenance right when they need it the most - when creating their backups.”
Integration Details:
OWC Innergize: Ensures OWC Atlas memory cards always deliver maximum performance and reliability with three key functions:
- Health Check – view a verified report of remaining flash lifespan
- Field Upgrade – keep firmware up to date for the latest speed and compatibility
- Sanitize – fully clear hidden data to prevent frame drops during video or burst capture.
Hedge OffShoot: Accelerates offloading and backup with advanced features:
- Fastest possible transfers - with checksum verification
- Filter, rename, and sort footage - during ingest
- Seamless support - for OWC Atlas cards and OWC readers
Together, the integration makes OffShoot not only one of the fastest ways to back up media, but also the most reliable, ensuring camera cards remain healthy and workflows stay uninterrupted.
IBC2025:
The OWC Innergize and Hedge OffShoot integration will be showcased during this week’s IBC2025, in the OWC Booth: Hall 7, Booth 7.A60 (RAI Amsterdam, September 12-15) and the Hedge Booth: Hall 7 — 7.A32.
About Other World Computing (OWC)
Founded in 1988, Other World Computing (OWC®) is a trusted leader in high-performance storage, docks, and memory card solutions that empower professionals in video and audio production, photography, and business with the tools to maximize the performance and reliability of their workflows seamlessly. OWC’s professional-grade storage, expansion, media cards, docks, and connectivity, as well as its apps and accessories, are built to last by the people who use them: creatives, businesses, and consumers. For further information, please visit www.owc.com. OWC can also be found on LinkedIn and X.
©2025 Other World Computing (OWC). All other brand and product names contained in this announcement may be trademarks or registered trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250911579810/en/
Contacts
PR Contact:
Nicole Gorman
Gorman Communications, for Other World Computing (OWC)
M: 508-397-0131
nicole.gorman@gormancommunications.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom